Clinical trial
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults…
NCT00478816 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00478816 |
|---|---|
| Title | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines |
| Official title | A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines |
| Lead sponsor | Novartis Vaccines, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prophylaxis of Avian Influenza Vaccine |
| Intervention type | Biological |
| Interventions | Fluad H5N1 Pandemic Influenza Vaccine |
| Enrollment | 58 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | May 25, 2007 |
| Last update posted | Dec 1, 2016 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: